4D Molecular Therapeutics · 3 hours ago
Director, Statistical Programming
Emeryville, CA
Full-time
Onsite
Director/Executive
$228K/yr - $256K/yr
13+ years exp4D Molecular Therapeutics is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Director of Statistical Programming will focus on applying programming methodology for implementing statistical analyses using SAS for in-house deliverables and performing quality review of outsourced statistical deliverables.
BiotechnologyGenetics
Responsibilities
Provide statistical programming leadership for an assigned indication that may consist of multiple clinical trials
Work closely with biostatisticians to review the SAP, and responsible in the development of data/analysis program specification based on the SAP
Maintain complete and auditable programming documentations for analysis of clinical trials
Contribute to the development, documentation and maintenance of reusable programming code library
Collaborate with IT to set-up/maintain the statistical computing infrastructure (e.g., SAS server)
May act as a biostatistician on small-scale projects
Collaborate with various functions to ensure robust CRF/EDC development, and quality data collection for the assigned clinical trials
Oversee the biometrics vendors to ensure the prompt and quality statistical deliverables
Provide quality review of outsourced statistical deliverables (including inhouse double programming to QC as needed) and coordinate the inhouse review comments
Contribute to the development of functional-level standards, SOPs, and work instructions and templates
Stay abreast of industry development in biostatistics/statistical programming fields and apply to appropriate systems and processes
Other duties as assigned, nothing in this job description restricts management’s right to assign or reassign duties and responsibilities to this job at any time
Qualification
Required
B.A./B.S. degree in statistics, computer science, or other quantitative science major required
B.A./B.S. with 17+ years, or M.A./M.S. with 13+ years
Strong SAS programming skills required with proficiency in SAS/BASE, SAS Macros, SAS/Stat and ODS
Excellent written and verbal communication skills and strong team player with demonstrated track record of success in cross-functional team environment
Displays excellent organization and time management skills, excellent attention to detail, and ability to multi-task in a fast-paced environment with shifting priorities and/or conflicting deadlines
Proven conceptual, analytical and strategic thinking
Good interpersonal and project management skills
Proactively identifies risks, issues, and possible solutions
Preferred
Advanced degree (M.A./M.S.) preferred, or equivalent experience
Experience in ophthalmology and/or biologic/gene therapy a plus
Proficiency in R programming a plus
Proficiency in Microsoft Office Apps, such as WORD, EXCEL, and PowerPoint (familiar with the “Chart” features in EXCEL/PowerPoint a plus)
Good understanding of standards specific to clinical trials such as CDISC, SDTM, and ADaM, MedDRA, WHODRUG
Experience with all clinical phases (I, II, III, and IV) is desirable
Experience with BLA/IND submissions is strongly desirable
Good understanding of regulatory requirements for submission-related activities (e.g., CDISC, CDASH, eCTD) and CRT packages (e.g., XPTs Define/xml, reviewer's guide, analysis metadata report, executable programs) is desirable
Able to run the P21 checks is a plus
Knowledge of applicable GCP/FDACHMP//ICH/HIPPA regulations
Company
4D Molecular Therapeutics
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
51-200 employees
H1B Sponsorship
4D Molecular Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2024 (3)
2023 (1)
2022 (1)
2021 (4)
Funding
Current Stage
Public CompanyTotal Funding
$702.5MKey Investors
Cystic Fibrosis FoundationViking Global Investors
2025-11-06Post Ipo Equity· $100M
2025-10-13Post Ipo Equity· $7.5M
2024-02-06Post Ipo Equity· $300M
Leadership Team
David Kirn
Co-Founder & CEO
L
Liansheng Zhu
Sr VP Biometrics and Data Quality
Recent News
2026-01-07
Longevity.Technology - Latest News, Opinions, Analysis and Research
2025-12-19
Benzinga.com
2025-12-19
Company data provided by crunchbase